MTRNR2L6

Across TCGA pan-cancer cohorts, MTRNR2L6 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of MTRNR2L6’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where MTRNR2L6 RNA is repressed in tumor relative to normal tissue. In most cancer types MTRNR2L6 is over-expressed in tumor, although a few such as LIHC and KIRC show the opposite, repressed pattern.

LIHC, KIRC, and STAD are the cancer types where MTRNR2L6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTRNR2L6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	All	−0.081	.005	6	view →
KIRC	Female	All	−0.129	.011	4	view →
STAD	Male	II,III,IV	−0.345	.040	2	view →
LUSC	Female	II,III,IV	+0.181	.029	2	view →
HNSC	Female	IV	−0.160	.016	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

MTRNR2L6–LIHC

Open the LIHC breakdown →